Second MTCH-24 Trials Yield Positive Results.Business Editors/Health & Medical Writers SCOTTSDALE, Ariz.--(BUSINESS WIRE)--May 8, 2000 Meditech Pharmaceuticals Inc. (MDCH-OTC:BB) announced today that Immune Network Research Ltd. (CDNX CDNX See Canadian Venture Exchange (CDNX). :IMM IMM See: International Monetary Market ) has confirmed that the second and most recent round of ongoing scientific studies with MTCH-24 have yielded additional positive results. Preliminary in-vitro efficacy tests indicate that MTCH-24 is active against both HSV-I and HSV-II and is less cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic than other compounds in its class. The laboratory report states that "preliminarily, MTCH-24 is active as a potent antiviral microbicide at levels at least twofold lower than those causing cytotoxicity cytotoxicity /cy·to·tox·ic·i·ty/ (si?to-tok-sis´i-te) the degree to which an agent possesses a specific destructive action on certain cells or the possession of such action. ." These studies are the second in a series of laboratory and clinical trials that have already been contracted by Immune Network. Additional clinical studies are planned to support Meditech's marketing efforts. Meditech Chief Executive Officer Gerald Kern stated that "the Company is extremely pleased with these results and anxiously looks forward to the commencement of clinical studies. Protocols for these studies are well into development and once the studies are complete, we will begin to execute our marketing plan." Kern further indicated that the initial product for the clinical trials has been manufactured and shipped to Immune Network's facility in Vancouver. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements contained in this release that are not historical facts are forward-looking statements subject to risks and uncertainties which could cause actual results to differ materially from those set forth in or implied by forward-looking statements. These risks are described in detail in the company's Securities and Exchange Commission filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion